Marlies de Graaf
Overview
Explore the profile of Marlies de Graaf including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
58
Citations
264
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
van der Rijst L, Veldhuis N, van der Kamp S, Achten R, van Luijk C, Voskuil-Kerkhof E, et al.
Pediatr Allergy Immunol
. 2025 Feb;
36(2):e70040.
PMID: 39905639
No abstract available.
2.
Boesjes C, van der Gang L, Bakker D, den Hartog Jager C, de Graaf M, de Bruin-Weller M, et al.
Clin Exp Allergy
. 2025 Feb;
55(3):260-263.
PMID: 39905630
No abstract available.
3.
Dekkers C, Zuithoff N, Bakker D, Knol E, Wevers A, Touwslager W, et al.
Allergy
. 2024 Dec;
PMID: 39673366
Introduction And Objectives: Tralokinumab-a biological that specifically targets interleukin-13-is one of the newer advanced systemic treatments for patients with moderate-to-severe atopic dermatitis (AD). Although safety and efficacy have been shown...
4.
van der Rijst L, Kamphuis E, Schuttelaar M, Hurmuz R, Seyger M, Caron A, et al.
JAMA Dermatol
. 2024 Oct;
161(1):12-21.
PMID: 39412782
Importance: Dupilumab, methotrexate (MTX), and cyclosporine A (CsA) are valuable treatment options for pediatric patients with refractory moderate to severe atopic dermatitis (AD). Yet, comparative data on these treatments in...
5.
van der Rijst L, de Winter-de Groot K, de Bruin-Weller M, de Graaf M
Pediatr Allergy Immunol
. 2024 Aug;
35(8):e14222.
PMID: 39158130
No abstract available.
6.
Boesjes C, Kamphuis E, de Graaf M, Spekhorst L, Haeck I, van der Gang L, et al.
JAMA Dermatol
. 2024 Aug;
160(10):1044-1055.
PMID: 39110432
Importance: Limited data are available on the long-term effectiveness and safety of dupilumab for atopic dermatitis (AD) in daily practice. Objective: To evaluate clinical effectiveness and reasons for discontinuation of...
7.
van der Rijst L, Hilbrands M, Zuithoff N, de Bruin-Weller M, Knulst A, Le T, et al.
Clin Transl Allergy
. 2024 Jul;
14(7):e12381.
PMID: 39019593
No abstract available.
8.
van der Rijst L, de Winter-de Groot K, Zuithoff N, de Bruin-Weller M, de Graaf M
Pediatr Allergy Immunol
. 2024 Jun;
35(6):e14178.
PMID: 38899688
Background: Atopic dermatitis (AD) is frequently associated with asthma and allergic rhinitis (AR). Dupilumab is an effective treatment for pediatric AD, although the effect on atopic comorbidities in pediatric AD...
9.
Zhang J, Boesjes C, Loman L, Kamphuis E, Romeijn M, Spekhorst L, et al.
J Am Acad Dermatol
. 2024 Apr;
91(2):300-311.
PMID: 38653344
Background: Long-term daily practice data on patient-reported benefits of dupilumab for atopic dermatitis (AD) remains limited. Objective: To evaluate patient-reported outcome measures (PROMs) and the safety of dupilumab in patients...
10.
Achten R, Thijs J, van der Wal M, van Luijk C, Bakker D, Knol E, et al.
Clin Exp Allergy
. 2024 Feb;
54(4):241-252.
PMID: 38332535
Atopic dermatitis (AD) is a chronic inflammatory skin disease for which new targeted therapies are currently available. Due to the increased rates of ocular surface disease (OSD) reported during treatment...